European Union · Record · CO
CELEX 62013CO0210
Order of the Court (Eighth Chamber), 14 November 2013.#Glaxosmithkline Biologicals SA and Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG v Comptroller General of Patents, Designs and Trade Marks.#Request for a preliminary ruling from the High Court of Justice (England and Wales), Chancery Division.#Medicinal products for human use — Supplementary protection certificate — Regulation (EC) No 469/2009 — Concepts of ‘active ingredient’ and ‘combination of active ingredients’ — Adjuvant.#Case C‑210/13.
Introduced
14 November 2013
Last action
—
Status
decided
Sponsors
—
Subjects
Discovery layer
Source updated
14 November 2013
Records
Official record CELEX 62013CO0210 from European Union at Court of Justice of the European Union. Dated 14 November 2013. Status: decided.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
23 official files
Order of the Court (Eighth Chamber), 14 November 2013.#Glaxosmithkline Biologicals SA and Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG v Comptroller General of Patents, Designs and Trade Marks.#Request for a preliminary ruling from the High Court of Justice (England and Wales), Chancery Division.#Medicinal products for human use — Supplementary protection certificate — Regulation (EC) No 469/2009 — Concepts of ‘active ingredient’ and ‘combination of active ingredients’ — Adjuvant.#Case C‑210/13.
judgment · EN · 14 November 2013
Digriet tal-Qorti tal-Ġustizzja (It-Tmien Awla) tal-14 ta’ Novembru 2013.#Glaxosmithkline Biologicals SA u Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG vs Comptroller General of Patents, Designs and Trade Marks.#Talba għal deċiżjoni preliminari mressqa mill-High Court of Justice (England & Wales), Chancery Division.#Prodotti mediċinali għall-użu mill-bniedem — Ċertifikat ta’ protezzjoni supplimentari — Regolament (KE) Nru 469/2009 — Kunċetti ta’ ‘ingredjent attiv’ u ta’ ‘kombinazzjoni ta’ ingredjenti attivi’ — Adjuvant.#Kawża C‑210/13.
judgment · MT · 14 November 2013
Uznesenie Súdneho dvora (ôsma komora) zo 14. novembra 2013.#Glaxosmithkline Biologicals SA a Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG proti Comptroller General of Patents, Designs and Trade Marks.#Návrh na začatie prejudiciálneho konania podaný High Court of Justice (England & Wales), Chancery Division.#Humánne lieky – Dodatkové ochranné osvedčenie – Nariadenie (ES) č. 469/2009 – Pojmy ,aktívna zložkaʻ a ,zlúčenina aktívnych zložiekʻ – Adjuvancium.#Vec C‑210/13.
judgment · SK · 14 November 2013
Usnesení Soudního dvora (osmého senátu) ze dne 14. listopadu 2013.#Glaxosmithkline Biologicals SA a Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG v. Comptroller General of Patents, Designs and Trade Marks.#Žádost o rozhodnutí o předběžné otázce podaná High Court of Justice (England & Wales), Chancery Division.#Humánní léčivé přípravky – Dodatková ochranná osvědčení – Nařízení (ES) č. 469/2009 – Pojmy ‚účinná látka‘ a ,kombinace účinných látek‘ – Adjuvans.#Věc C‑210/13.
judgment · CS · 14 November 2013
Beschikking van het Hof (Achtste kamer) van 14 november 2013.#Glaxosmithkline Biologicals SA en Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG tegen Comptroller General of Patents, Designs and Trade Marks.#Verzoek van de High Court of Justice (England and Wales), Chancery Division, om een prejudiciële beslissing.#Geneesmiddelen voor menselijk gebruik – Aanvullend beschermingscertificaat – Verordening (EG) nr. 469/2009 – Begrippen ‚werkzame stof’ en ‚samenstelling van werkzame stoffen’ – Adjuvans.#Zaak C‑210/13.
judgment · NL · 14 November 2013
A Bíróság végzése (nyolcadik tanács), 2013. november 14.#Glaxosmithkline Biologicals SA és Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG kontra Comptroller General of Patents, Designs and Trade Marks.#A High Court of Justice (England & Wales), Chancery Division (Egyesült Királyság) által benyújtott előzetes döntéshozatal iránti kérelem.#Emberi felhasználásra szánt gyógyszerek – Kiegészítő oltalmi tanúsítvány – 469/2009/EK rendelet – A »hatóanyag« és a »hatóanyagok kombinációja« fogalma – Adjuváns.#C‑210/13. sz. ügy.
judgment · HU · 14 November 2013
2013 m. lapkričio 14 d. Teisingumo Teismo (aštuntoji kolegija) nutartis.#Glaxosmithkline Biologicals SA ir Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. kg prieš Comptroller General of Patents, Designs and Trade Marks.#High Court of Justice (England & Wales), Chancery Division prašymas priimti prejudicinį sprendimą.#Žmonėms skirti vaistai – Papildomos apsaugos liudijimas – Reglamentas (EB) Nr. 469/2009 – Sąvokos „veiklioji sudedamoji dalis“ ir „veikliųjų sudedamųjų dalių derinys“ – Adjuvantas.#Byla C-210/13.
judgment · LT · 14 November 2013
Ordonanța Curții (Camera a opta) din 14 noiembrie 2013.#Glaxosmithkline Biologicals SA și Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG împotriva Comptroller General of Patents, Designs and Trade Marks.#Cerere de decizie preliminară formulată de High Court of Justice (England & Wales), Chancery Division.#Medicamente de uz uman – Certificat suplimentar de protecție – Regulamentul (CE) nr. 469/2009 – Noțiunile „principiu activ” și „compoziție de principii active” – Adjuvant.#Cauza C-210/13.
judgment · RO · 14 November 2013
Postanowienie Trybunału (ósma izba) z dnia 14 listopada 2013 r.#Glaxosmithkline Biologicals SA i Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. przeciwko Comptroller General of Patents, Designs and Trade Marks.#Wniosek o wydanie orzeczenia w trybie prejudycjalnym złożony przez High Court of Justice (England & Wales), Chancery Division.#Produkty lecznicze stosowane u ludzi – Dodatkowe świadectwo ochronne – Rozporządzenie (WE) nr 469/2009 – Pojęcia „aktywnego składnika” i „mieszaniny aktywnych składników” – Adjuwant.#Sprawa C-210/13.
judgment · PL · 14 November 2013
Ordonnance de la Cour (huitième chambre) du 14 novembre 2013.#Glaxosmithkline Biologicals SA et Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG contre Comptroller General of Patents, Designs and Trade Marks.#Demande de décision préjudicielle, introduite par High Court of Justice (England & Wales), Chancery Division.#Médicaments à usage humain – Certificat complémentaire de protection – Règlement (CE) nº 469/2009 – Notions de ‘principe actif’ et de ‘composition de principes actifs’ – Adjuvant.#Affaire C‑210/13.
judgment · FR · 14 November 2013
Unionin tuomioistuimen määräys (kahdeksas jaosto) 14.11.2013.#Glaxosmithkline Biologicals SA ja Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG vastaan Comptroller General of Patents, Designs and Trade Marks.#High Court of Justice (England & Wales), Chancery Divisionin esittämä ennakkoratkaisupyyntö.#Ihmisille tarkoitetut lääkkeet – Lisäsuojatodistus – Asetus (EY) N:o 469/2009 – Käsitteet ”vaikuttava aine” ja ”vaikuttavien aineiden yhdistelmä” – Tehosteaine.#Asia C-210/13.
judgment · FI · 14 November 2013
Ordinanza della Corte (Ottava Sezione) del 14 novembre 2013.#Glaxosmithkline Biologicals SA e Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG contro Comptroller General of Patents, Designs and Trade Marks.#Domanda di pronuncia pregiudiziale proposta dalla High Court of Justice (England & Wales), Chancery Division.#Medicinali per uso umano – Certificato protettivo complementare – Regolamento (CE) n. 469/2009 – Nozioni di “principio attivo” e di “composizione di principi attivi” – Adiuvante.#Causa C‑210/13.
judgment · IT · 14 November 2013
Tiesas astotā palātas priekšsēdētāja 2013. gada 14. novembra rīkojums.#Glaxosmithkline Biologicals SA un Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG pret Comptroller General of Patents, Designs and Trade Marks.#High Court of Justice (Chancery Division) lūgums sniegt prejudiciālu nolēmumu.#Cilvēkiem paredzētas zāles – Papildu aizsardzības sertifikāts – Regula (EK) Nr. 469/2009 – Jēdzieni “aktīvā viela” un “aktīvo vielu kombinācija” – Adjuvants.#Lieta C‑210/13.
judgment · LV · 14 November 2013
Rješenje predsjednika osmog vijeća Suda od 14. studenoga 2013.#Glaxosmithkline Biologicals SA i Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG protiv Comptroller-General of Patents, Designs and Trade Marks.#Zahtjev za prethodnu odluku koji je uputio High Court of Justice (England & Wales), Chancery Division.#Lijekovi za primjenu kod ljudi – Svjedodžba o dodatnoj zaštiti – Uredba (EZ) br. 469/2009 – Pojam ,aktivnog sastojka’ i ,mješavine aktivnih sastojaka’ – Adjuvans.#Predmet C-210/13.
judgment · HR · 14 November 2013
Sklep Sodišča (osmi senat) z dne 14. novembra 2013.#Glaxosmithkline Biologicals SA in Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG proti Comptroller General of Patents, Designs and Trade Marks.#Predlog za sprejetje predhodne odločbe, ki ga je vložilo High Court of Justice (England & Wales), Chancery Division.#Zdravila za uporabo v humani medicini – Dodatni varstveni certifikat – Uredba (ES) št. 469/2009 – Pojma ‚učinkovina‘ in ‚kombinacija učinkovin‘ – Dodatek.#Zadeva C‑210/13.
judgment · SL · 14 November 2013
Despacho do Tribunal de Justiça (Oitava Secção) de 14 de novembro de 2013.#Glaxosmithkline Biologicals SA e Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG contra Comptroller General of Patents, Designs and Trade Marks.#Pedido de decisão prejudicial apresentado pela High Court of Justice (England & Wales), Chancery Division (Patents Court).#Medicamentos para uso humano — Certificado complementar de proteção — Regulamento (CE) n.° 469/2009 — Conceitos de ‘princípio ativo’ e de ‘associação de princípios ativos’ — Adjuvante.#Processo C‑210/13.
judgment · PT · 14 November 2013
Διάταξη του Δικαστηρίου (όγδοο τμήμα) της 14ης Νοεμβρίου 2013.#Glaxosmithkline Biologicals SA και Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG κατά Comptroller General of Patents, Designs and Trade Marks.#Αίτηση του High Court of Justice (England & Wales), Chancery Division για την έκδοση προδικαστικής αποφάσεως.#Φάρμακα που προορίζονται για ανθρώπινη χρήση — Συμπληρωματικό πιστοποιητικό προστασίας — Κανονισμός (ΕΚ) 469/2009 — Έννοια των όρων «δραστική ουσία» και «σύνθεση δραστικών ουσιών» — Ανοσοενισχυτικό συμπλήρωμα.#Υπόθεση C‑210/13.
judgment · EL · 14 November 2013
Auto del Tribunal de Justicia (Sala Octava) de 14 de noviembre de 2013.#Glaxosmithkline Biologicals SA y Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG contra Comptroller General of Patents, Designs and Trade Marks.#Petición de decisión prejudicial planteada por la High Court of Justice (England & Wales), Chancery Division.#Medicamentos para uso humano — Certificado complementario de protección — Reglamento (CE) nº 469/2009 — Conceptos de “principio activo” y “composición de principios activos” — Adyuvante.#Asunto C‑210/13.
judgment · ES · 14 November 2013
Domstolens kendelse (Ottende Afdeling) af 14. november 2013.#Glaxosmithkline Biologicals SA og Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG mod Comptroller General of Patents, Designs and Trade Marks.#Anmodning om præjudiciel afgørelse indgivet af High Court of Justice (England & Wales), Chancery Division.#Humanmedicinske lægemidler – supplerende beskyttelsescertifikat – forordning (EF) nr. 469/2009 – begreberne »aktiv ingrediens« og »sammensætning af aktive ingredienser« – adjuvans.#Sag C-210/13.
judgment · DA · 14 November 2013
Domstolens beslut (åttonde avdelningen) av den 14 november 2013.#Glaxosmithkline Biologicals SA och Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG mot Comptroller General of Patents, Designs and Trade Marks.#Begäran om förhandsavgörande från High Court of Justice (England & Wales), Chancery Division.#Humanläkemedel – Tilläggsskydd – Förordning (EG) nr 469/2009 – Begreppen ’aktiv ingrediens’ och ’kombination av aktiva ingredienser’ – Adjuvans.#Mål C‑210/13.
judgment · SV · 14 November 2013
Определение на Съда (осми състав) от 14 ноември 2013 г.#Glaxosmithkline Biologicals SA и Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG срещу Comptroller General of Patents, Designs and Trade Marks.#Преюдициално запитване, отправено от High Court of Justice (England & Wales), Chancery Division.#Лекарствени продукти за хуманна употреба — Сертификат за допълнителна закрила на лекарствените продукти — Регламент (ЕО) № 469/2009 — Понятие за активна съставка и за комбинация от активни съставки — Адювант.#Дело C‑210/13.
judgment · BG · 14 November 2013
Beschluss des Gerichtshofs (Achte Kammer) vom 14. November 2013.#Glaxosmithkline Biologicals SA und Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG gegen Comptroller General of Patents, Designs and Trade Marks.#Vorabentscheidungsersuchen des High Court of Justice (England & Wales), Chancery Division.#Humanarzneimittel – Ergänzendes Schutzzertifikat – Verordnung (EG) Nr. 469/2009 – Begriffe ‚Wirkstoff‘ und ‚Wirkstoffzusammensetzung‘ – Adjuvans.#Rechtssache C‑210/13.
judgment · DE · 14 November 2013
Euroopa Kohtu määrus (kaheksas koda), 14.11.2013.#Glaxosmithkline Biologicals SA ja Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG versus Comptroller General of Patents, Designs and Trade Marks.#Eelotsusetaotlus, mille on esitanud High Court of Justice (England & Wales), Chancery Division.#Inimtervishoius kasutatavad ravimid – Täiendava kaitse tunnistus – Määrus (EÜ) nr 469/2009 – Mõisted „toimeaine” ja „toimeainete kombinatsioon” – Vaktsiiniabiaine.#Kohtuasi C‑210/13.
judgment · ET · 14 November 2013
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.